Caredx Inc Stock
Your prediction
Caredx Inc Stock
CareDx is a publicly traded biotechnology company that specializes in providing innovative transplant solutions for patients suffering from various diseases. The company has developed a range of diagnostic solutions that help doctors monitor the health of organ transplant recipients, including tests that can detect early signs of organ rejection. CareDx has a strong track record of developing cutting-edge medical technologies and working with leading healthcare providers to improve patient outcomes. As a publicly-listed company, CareDx has a diverse shareholder base and is subject to the scrutiny of regulatory bodies, providing transparency and accountability to investors.
Pros and Cons of Caredx Inc in the next few years
Pros
Cons
Performance of Caredx Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Caredx Inc | 13.860% | 15.854% | 47.287% | 252.996% | 132.843% | 281.910% | -46.479% |
| Evolus Inc | -0.040% | -0.496% | -14.130% | -33.154% | -4.330% | -42.703% | -41.085% |
| Heron Therapeutics Inc. | -1.990% | 2.964% | 15.558% | -71.508% | -61.329% | -69.229% | -95.846% |
| Rhythm Pharmaceuticals | -1.080% | 1.667% | -5.181% | 26.207% | -2.139% | 479.114% | 535.417% |
News
Why CareDx Stock Jumped Today
Shares of CareDx (NASDAQ: CDNA) climbed on Friday after the precision medicine diagnostics specialist lifted its full-year sales and earnings forecast.
Image source: Getty Images.
CareDx's revenue
CareDx Q2 Earnings Call Highlights
Key Points
- Interested in CareDx, Inc.? Here are five stocks we like better.
- CareDx’s second-quarter revenue rose 52% to $132 million, driven by a 61% increase in testing-services revenue and a
CareDx's CEO Sells 17K Shares
CareDx (NASDAQ:CDNA), a leader in transplant diagnostics, saw a key insider reduce his direct holdings amid a series of scheduled transactions.
John Hanna, President and CEO of CareDx, disclosed the